Hudu Mogtari, M.B.A., is the former chief executive officer (CEO) of the Food and Drugs Authority (FDA) of Ghana. He holds an Executive MBA degree from the Ghana Institute of Management and Public Administration and a BSc Pharm from the University of Hacettepe in Ankara, Turkey. He was awarded a certificate in Strategic Management in Regulatory and Enforcement Agencies at the Harvard Kennedy School of Government. He also has training in Clinical Investigation by the Centre for Drug Evaluation and Research of the U.S. FDA, advanced training in Diabetes and Endocrinology at the Centre for Diabetes and Endocrinology in South Africa as well as training at the United States Pharmacopoeia. Mr. Mogtari has over 20 years’ experience as a pharmacist and he was the country manager for Eli Lilly prior to his appointment as the CEO of the FDA. Under his leadership the FDA has achieved ISO 17025 accreditation for its Drugs Physico-Chemical Laboratory. The FDA has also been designated as a Regional Centre of Regulatory Excellence in the area of Medicines Evaluation and Registration as well as Clinical Trials Oversight.
Clare Narrod, Ph.D., M.S., is the director of the Risk Analysis program at Joint Institute For Food Safety And Applied Nutrition (JIFSAN) and leads the monitoring and impact effort associated with the evaluation of JIFSAN's capacity building efforts. She received her Ph.D. in Energy Management and Environmental Policy in 1997 and a Master's Degree in International Development and Appropriate Technology both from the University of Pennsylvania. From 1998-2000 she served as an American Association for the Advancement of Science Risk Analysis fellow at USDA. Prior to coming to JIFSAN she worked at the International Food Policy Research Institute, the United States Department of Agriculture, and at the Food and Agriculture Organization. She has consulted for the World Bank and the Inter-American Institute for Cooperation on Agriculture. She has field experience in Brazil, China, Costa Rica, Ethiopia, Ghana, India, Indonesia, Kenya, Nigeria, Thailand, Mali, Mexico, Vietnam, and Zambia. She has taught in Colombia, China, India, Malaysia, Russia, and the US. She started her career in the government where she conducted and reviewed risk assessments and cost-benefit analyses of proposed and final rules for Agency clearance associated with reducing the risk of animal and plant diseases and improving food safety. In addition to her work at JIFSAN she is also a scientific advisory board member of the Institute for Food and Agricultural Literacy at UC Davis, World Food Center and on the board of directors for the Center for Foodborne Illness, Research & Prevention. In the past she has been a working group member on a Global Food Ethics Project at John Hopkins Berman Institute for Bioethics, a member of the expert panel for a Global Regulatory Competency and Curricula, and a consensus committee member on the Institute of Medicine’s study on "Strengthening Core Elements of Food Safety Regulatory Systems in Developing Countries."
Jonathan Quick, M.D., M.P.H., is senior fellow emeritus at MSH, where he previously served as president and chief executive officer from 2004-2017. In January of 2017 he transitioned to the role of Senior Fellow. A family physician and health management specialist, Dr. Quick focuses on global health security. He is the author of The End of Epidemics: The Looming Threat to Humanity and How to Stop It. Dr. Quick was director of essential drugs and medicines policy at the World Health Organization from 1996 to 2003. Prior to that, he served with MSH as founding director of the drug management program/center for pharmaceutical management, then as a long-term advisor for the Afghanistan Health Sector Support Project and the Kenya Health Care Financing Project. He has worked in international health since 1978 and has carried out assignments in over 70 countries in Africa, Asia, Latin America, and the Middle East. He is the senior editor of Managing Drug Supply, co-author of the Financial Times Guide to Executive Health; and has written over 100 other books, articles, and chapters. He is on the faculty of Harvard Medical School Department of Global Health and Social Medicine and Boston University School of Public Health, and is a fellow of the Royal Society of Medicine. He has a first degree from Harvard University and an M.D., with distinction in research, and M.P.H. from the University of Rochester.
Joshua M. Sharfstein
Joshua Sharfstein, M.D., is vice dean for Public Health Practice and Community Engagement and professor of the Practice in Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. He is also the director of the Bloomberg American Health Initiative. Previously, Dr. Sharfstein served as secretary of the Maryland Department of Health and Mental Hygiene, as principal deputy commissioner of the U.S. Food and Drug Administration, and as health commissioner of Baltimore City. In these positions, he pursued creative solutions to longstanding challenges, including drug overdose deaths, infant mortality, unsafe consumer products, and school failure. He is an elected member of the National Academy of Medicine and the National Academy of Public Administration.
Markus Taussig, D.B.A., is an associate professor in the Management and Global Business Department at Rutgers Business School. Previous to his doctoral studies in strategy at Harvard Business School, Markus lived in Vietnam for 11 years, where he researched development of that country’s nascent private sector for the World Bank, The Asia Foundation, and various bilateral aid organizations. His academic work on business strategy in developing countries has been published in the Strategic Management Journal, Journal of Law, Economics and Organization, Journal of International Business Studies, Journal of East Asian Studies and Business Horizons. His more recent work on strategies for increasing regulatory compliance in developing countries in the Academy of Management Journal and the American Political Science Review was funded by the Jameel Poverty Action Lab, World Bank, and National University of Singapore, and has received best paper awards from the Academy of Management’s Public and Non-Profit Division and the International Association for Chinese Management Research. He is currently working on follow up studies on regulatory compliance in Myanmar and Malaysia.
Raymond Wigenge, M.Sc., M.B.A., is a food technologist with over 25 years experience in food safety and regulation. He attained his M.Sc. in Food Science and Technology at Ghent University Belgium in 1997. He is also a holder of B.Sc. Food Science and Technology obtained at Sokoine University of Agriculture, Tanzania in 1989. Other academic qualifications include M.B.A. obtained in year 2013 at Eastern and Southern African Management Institute, Arusha, Tanzania and a diploma in animal production in 1980 in Mbeya Tanzania. Since 1982, he has been employed as a public servant and served in different capacities such as Livestock Extension Officer and agricultural tutor for three and half years. He has served in different roles, including: food control officer, chief food inspector, Zone Offices and Local Government Authority coordinator, and as director of Food Safety for the Tanzanian Food and Drug Authority (FDA). During his career, he developed food regulations and guidelines, conducted food inspections, and was engaged in developing and implementing the food safety control system in Tanzania. He led development of the draft national food safety policy. He also designed a system for surveillance and investigation of food borne diseases and acted as a key liaison between the Tanzania FDA and UN agencies such as FAO, WHO, the Codex Alimentarius Commission.
Veronika Wirtz, M.Sc., Ph.D., is an associate professor in the Department of Global Health at the Boston University School of Public Health, where she is also director of the World Health Organization Collaborating Center in Pharmaceutical Policy. Her research focuses on health system strengthening and policy and program evaluations of medicines access and utilization. She is a visiting professor of the National Institute of Public Health (INSP) in Mexico and coordinator of a student exchange program between the institutions of her affiliation. Her interest and expertise include medicines price analysis, generic medicines policies, quality use of medicines, access to medicines for non-communicable diseases and the role of the private sector to promote equitable access and efficient use of medicines in low and middle income countries. Between 2014 and 2016 she was the co-chair of The Lancet Commission on Essential Medicine Policies. From 2004 to 2012 she was researcher and lecturer at the National INSP in Mexico and a founding member and Head of the Medicines in Public Health Research Group which is a multi-disciplinary team of 15 experts in health economics, epidemiology, social science carrying out pharmaceutical policy analysis in Mexico and Latin America. Over the last years she has regularly taught short courses in Pharmacoepidemiology and Medicines Utilization Research at INSP in Mexico. She has worked as a technical adviser for various international organizations, among them the World Health Organization, the Pan American Health Organization, the Global Fund to fight AIDS, Tuberculosis and Malaria, the Bill and Melinda Gates Foundation, Alliance for Health Systems and Policy Research, Health Action International and the Ford Foundation. She has also worked with the Ministry of Health in Mexico on various program evaluations and capacity building initiatives. She published widely in international peer review journals such as The Lancet, British Medical Journal, World Health Organization Bulletin, Health Policy and Planning, Health Policy, Value in Health, Social Science and Medicine, Tropical Medicine and International Health. Since Fall 2016 she is associate editor of Health Systems & Reform, a leading journal publishing health system and policy research. She received her training as a pharmacist from Albert-Ludwigs-University in Freiburg, Germany and her Master in Clinical Pharmacy and Ph.D. from the University of London in the UK.
Prashant Yadav, M.B.A., Ph.D., is a globally recognized scholar in the area of healthcare supply chains. He is the author of many peer-reviewed scientific publications and his work has also been featured in prominent print and broadcast media including The Economist, The Financial Times, Nature, and BBC. Outside academia, Dr. Yadav works closely with governments and global organizations in the area of policy and investment strategy design for healthcare supply chains. He currently works as Strategy Leader-Supply Chain at the Bill & Melinda Gates Foundation. Dr. Yadav serves on the advisory boards of many global organizations and social enterprises. He has been invited for expert testimony on the issue of medicine supply chains in the US Congress and legislative bodies in other countries. He was a Commissioner on the Lancet Commission on Essential Medicines and has been a member of multiple national Academy of Medicine Expert Committees. He was Chair of the Market Dynamics Advisory Group of the Global Fund to fight AIDS, TB and Malaria, Geneva and Co-chair of Procurement and Supply Chain Management at the Roll Back Malaria Partnership. Prashant’s research papers have been the recipient of the best paper awards from the Production and Operations Management Society, INFORMS, and other professional societies. He was inducted as a Chartered Fellow of the CILT in 2011. Before his current role, Dr. Yadav was vice president of healthcare at the William Davidson Institute at the University of Michigan and a faculty member at the Ross School of Business at the University of Michigan. Before that he was professor of Supply Chain Management at the MIT-Zaragoza International Logistics Program and a research affiliate at the MIT Center for Transportation and Logistics.